Chronotherapy With Once-Daily Osilodrostat Improves Cortisol Rhythm, Quality of Life, and Sleep in Cushing's Syndrome
Open accessThe DOI matches its Crossref record; 70 of the 71 references it cites were found in a registry or an index.
Abstract
Context: Medical therapy for Cushing syndrome (CS) typically aims to reduce daily cortisol output without addressing circadian rhythm restoration. No licensed drugs target this goal. Objective: We investigated the efficacy and safety of timed, once-daily osilodrostat administration in improving circadian cortisol profiles in CS. Methods: A prospective, multicenter study evaluated patients with well-controlled CS on a stable twice-daily osilodrostat therapy before and 60 to 90 days after transitioning to a single equivalent daily dose at 19:00 ± 1 hour. Circadian steroid analysis was performed on saliva, serum, and urine using ultra-high performance liquid chromatography–tandem mass spectrometry. Additional assessments included cardio-metabolic markers, quality of life, sleep function, and safety outcomes. Results: Sixteen patients (4 males; 7 pituitary, mean age 53.3 ± 11.8 years) were enrolled. At baseline, CS was well-controlled with a mean osilodrostat dose of 4.2 ± 1.3 mg. After transitioning, salivary cortisol exposure decreased significantly during the afternoon to early morning period (AUC16:00-08:00: −6.1 [−0.15 to −12.1] ng/mL/h, P = .029). Quality of life and sleep improved (CushingQoL: +4.2, P = .029; Pittsburgh Sleep Quality Index: −1.7, P = .049). Serum steroid precursors, including 11-deoxycorticosterone (−3.1 ng/mL/h, P = .008) and 11-deoxycortisol (−17.8 ng/mL/h, P = .005), decreased. Eight patients advancing dosing to 16:00 ± 1 hour showed comparable reductions, with phase shifts in acrophase and nadir. No patients developed adrenal insufficiency, liver toxicity, electrocardiogram abnormalities, or loss of disease control. Conclusion: Once-daily osilodrostat effectively and safely treats patients with biochemically controlled CS, improving circadian cortisol profiles, quality of life, and sleep. Findings support further exploration of chronotherapy-based approaches in CS management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, evidence suggests that restoring cortisol circadian rhythm may improve disease control and alleviate symptoms (39-43).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“Although this can be achieved after successful surgery selectively removing the source of excess ACTH or cortisol, normalization of the cortisol circadian rhythm after most medical therapies has rarely been investigated and is not routinely measured to assess treatment response (39-44).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“Once-daily osilodrostat dosing significantly reduced late afternoon to early morning cortisol exposure while maintaining morning peak concentrations, thereby improving cortisol circadian rhythms even in patients with well-controlled CS.”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, patient-reported outcomes of quality of life and sleep showed significant improvement.”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90047-4 · Cited by 35,234
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Consensus on diagnosis and management of Cushing's disease: a guideline update
Fleseriu, M., Auchus, R., Bancos, I., Ben-Shlomo, A., Bertherat, J., Biermasz, N. R., Boguszewski, C. L., Bronstein, M. D., Buchfelder, M., Carmichael, J. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00235-7 · Cited by 953
Self-citationComplications of Cushing's syndrome: state of the art
Pivonello, R., Isidori, A. M., De Martino, M. C., Newell-Price, J., Biller, B. M. K., & Colao, A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00086-3 · Cited by 641
Self-citationThe Treatment of Cushing's Disease
Pivonello, R., De Leo, M., Cozzolino, A., & Colao, A. (2015) · Endocrine Reviews · doi:10.1210/er.2013-1048 · Cited by 465
Self-citationDiagnosis and Management of Pituitary Adenomas: A Review
Tritos, N. A., & Miller, K. K. (2023) · JAMA · doi:10.1001/jama.2023.5444 · Cited by 331
Reincke, M., & Fleseriu, M. (2023) · JAMA · doi:10.1001/jama.2023.11305 · Cited by 256
Webb, S. M., Badia, X., Barahona, M. J., Colao, A., Strasburger, C. J., Tabarin, A., van Aken, M. O., Pivonello, R., Stalla, G., Lamberts, S. W. J., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0762 · Cited by 229
Self-citationPivonello, R., Fleseriu, M., Newell-Price, J., Bertagna, X., Findling, J., Shimatsu, A., Gu, F., Auchus, R., Leelawattana, R., Lee, E. J., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30240-0 · Cited by 222
Self-citationIsidori, A. M., Venneri, M. A., Graziadio, C., Simeoli, C., Fiore, D., Hasenmajer, V., Sbardella, E., Gianfrilli, D., Pozza, C., Pasqualetti, P., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30398-4 · Cited by 211
Self-citationBertagna, X., Pivonello, R., Fleseriu, M., Zhang, Y., Robinson, P., Taylor, A., Watson, C. E., Maldonado, M., Hamrahian, A. H., Boscaro, M., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2117 · Cited by 189
Self-citationIsidori, A. M., Graziadio, C., Paragliola, R. M., Cozzolino, A., Ambrogio, A. G., Colao, A., Corsello, S. M., & Pivonello, R. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000415 · Cited by 185
Self-citationCircadian endocrine rhythms: the hypothalamic–pituitary–adrenal axis and its actions
Nicolaides, N. C., Charmandari, E., Chrousos, G. P., & Kino, T. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12464 · Cited by 183
Neuropsychiatric disorders in Cushing's syndrome
Pivonello, R., Simeoli, C., De Martino, M. C., Cozzolino, A., De Leo, M., Iacuaniello, D., Pivonello, C., Negri, M., Pellecchia, M. T., Iasevoli, F., et al. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00129 · Cited by 174
Self-citationThe Cortisol Awakening Response in Context
Clow, A., Hucklebridge, F., & Thorn, L. (2010) · International Review of Neurobiology · doi:10.1016/s0074-7742(10)93007-9 · Cited by 169
Gadelha, M., Gatto, F., Wildemberg, L. E., & Fleseriu, M. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01961-x · Cited by 168
Fleseriu, M., Pivonello, R., Young, J., Hamrahian, A. H., Molitch, M. E., Shimizu, C., Tanaka, T., Shimatsu, A., White, T., Hilliard, A., et al. (2016) · Pituitary · doi:10.1007/s11102-015-0692-z · Cited by 155
Self-citationThe Immune System in Cushing’s Syndrome
Hasenmajer, V., Sbardella, E., Sciarra, F., Minnetti, M., Isidori, A. M., & Venneri, M. A. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.04.004 · Cited by 147
Self-citationKrueger, D. C., Tanner, S. B., Szalat, A., Malabanan, A. O., Prout, T. M., Lau, A., Rosen, H. N., & Shuhart, C. (2023) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2023.101437 · Cited by 124
Randomized trial of osilodrostat for the treatment of Cushing disease
Gadelha, M., Bex, M., Feelders, R. A., Heaney, A. P., Auchus, R. J., Gilis-Januszewska, A., Witek, P., Belaya, Z., Yu, Y., Liao, Z., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac178 · Cited by 114
The diagnosis of Cushing’s syndrome
Carroll, T. B., & Findling, J. W. (2010) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-010-9143-3 · Cited by 107
The Pathophysiology and Treatment of Hypertension in Patients With Cushing's Syndrome
Barbot, M., Ceccato, F., & Scaroni, C. M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00321 · Cited by 104
Debono, M., Harrison, R. F., Chadarevian, R., Gueroult, C., Abitbol, J.-L., & Newell-Price, J. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00823 · Cited by 100
Martino, T. A., Tata, N., Simpson, J. A., Vanderlaan, R., Dawood, F., Kabir, M. G., Khaper, N., Cifelli, C., Podobed, P., Liu, P. P., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.022 · Cited by 94
Cushing's syndrome: Treatment and new therapeutic approaches
Ferrière, A., & Tabarin, A. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101381 · Cited by 90
Dormoy, A., Haissaguerre, M., Vitellius, G., Cao, C. D., Geslot, A., Drui, D., Lasolle, H., Vieira-Pinto, O., Salenave, S., François, M., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac691 · Cited by 82
Venneri, M. A., Hasenmajer, V., Fiore, D., Sbardella, E., Pofi, R., Graziadio, C., Gianfrilli, D., Pivonello, C., Negri, M., Naro, F., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00346 · Cited by 80
Self-citationAn individualized approach to the management of Cushing disease
Fleseriu, M., Varlamov, E. V., Hinojosa‐Amaya, J. M., Langlois, F., & Melmed, S. K. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00868-7 · Cited by 80
Creemers, S. G., Feelders, R. A., de Jong, F. H., Franssen, G. J. H., de Rijke, Y. B., van Koetsveld, P. M., & Hofland, L. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00217 · Cited by 70
Fixing the broken clock in adrenal disorders: focus on glucocorticoids and chronotherapy
Minnetti, M., Hasenmajer, V., Pofi, R., Venneri, M. A., Alexandraki, K. I., & Isidori, A. M. (2020) · Journal of Endocrinology · doi:10.1530/joe-20-0066 · Cited by 70
Self-citationHome waking salivary cortisone to screen for adrenal insufficiency
Debono, M., Elder, C. J., Lewis, J., Fearnside, J., Caunt, S., Dixon, S., Jacques, R. M., Newell-Price, J., Whitaker, M. J., Keevil, B., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2200182 · Cited by 66
Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease
Newell-Price, J., Pivonello, R., Tabarin, A., Fleseriu, M., Witek, P., Gadelha, M. R., Petersenn, S., Tauchmanova, L., Ravichandran, S., Gupta, P., et al. (2020) · European Journal of Endocrinology · doi:10.1530/eje-19-0695 · Cited by 60
Self-citationVarlamov, E. V., Langlois, F., Vila, G., & Fleseriu, M. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-1309 · Cited by 58
Is urinary free cortisol of value in the diagnosis of Cushingʼs syndrome?
Alexandraki, K. I., & Grossman, A. B. (2011) · Current Opinion in Endocrinology, Diabetes and Obesity · doi:10.1097/med.0b013e3283487193 · Cited by 57
Fleseriu, M., & Biller, B. M. K. (2022) · Pituitary · doi:10.1007/s11102-022-01268-2 · Cited by 54
The influence of circadian rhythms and aerobic glycolysis in autism spectrum disorder
Vallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-01086-9 · Cited by 44
Moreira, A. C., Antonini, S. R. R., & de Castro, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0102 · Cited by 41
Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing's disease
van der Pas, R., de Bruin, C., Pereira, A. M., Romijn, J. A., Netea-Maier, R. T., Hermus, A. R., Zelissen, P. M., de Jong, F. H., van der Lely, A. J., de Herder, W. W., et al. (2013) · Pituitary · doi:10.1007/s11102-012-0452-2 · Cited by 39
Chronotherapeutics — A chronopharmaceutical approach to drug delivery in the treatment of asthma
Nainwal, N. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.09.012 · Cited by 39
Minnetti, M., Hasenmajer, V., Sbardella, E., Angelini, F., Simeoli, C., Di Paola, N., Cozzolino, A., Pivonello, C., De Alcubierre, D., Chiloiro, S., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0454 · Cited by 39
Self-citationMenard, J., Watson, C., Rebello, S., Zhang, Y. M., & Dole, W. P. (2010) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(10)60584-0 · Cited by 38
Bonnet-Serrano, F., Poirier, J., Vaczlavik, A., Laguillier, C., Blanchet, B., Baron, S., Guignat, L., Bessiène, L., Bricaire, L., Groussin, L., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0208 · Cited by 37
Kannankeril, J., Carroll, T., Findling, J. W., Javorsky, B., Gunsolus, I. L., Phillips, J., & Raff, H. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa107 · Cited by 36
Prolonged adrenocortical blockade following discontinuation of Osilodrostat
Poirier, J., Bonnet-Serrano, F., Thomeret, L., Bouys, L., & Bertherat, J. Y. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad060 · Cited by 36
Ferrière, A., Salenave, S., Puerto, M., Young, J., & Tabarin, A. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad167 · Cited by 33
Clinical Utility of Osilodrostat in Cushing’s Disease: Review of Currently Available Literature
Perosevic, M., & Tritos, N. A. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s315359 · Cited by 32
Mondin, A., Ceccato, F., Voltan, G., Mazzeo, P., Manara, R., Denaro, L., Scaroni, C. M., & Barbot, M. (2023) · Pituitary · doi:10.1007/s11102-023-01343-2 · Cited by 31
Findling, J. W., Fleseriu, M., Newell-Price, J., Petersenn, S., Pivonello, R., Kandra, A., Pedroncelli, A. M., & Biller, B. M. K. (2016) · Endocrine · doi:10.1007/s12020-016-0978-6 · Cited by 30
Self-citationHasenmajer, V., Sbardella, E., Sciarra, F., Simeoli, C., Pivonello, C., Ceccato, F., Pofi, R., Minnetti, M., Rizzo, F., Ferrari, D., et al. (2024) · eBioMedicine · doi:10.1016/j.ebiom.2024.105462 · Cited by 29
Self-citationMANAGEMENT OF ENDOCRINE DISEASE: Can we cure Cushing’s disease? A personal view
BERTAGNA, X. Y. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0062 · Cited by 27
Harrison, R. F., Debono, M., Whitaker, M. J., Keevil, B. G., Newell-Price, J., & Ross, R. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01172 · Cited by 27
Selectivity of osilodrostat as an inhibitor of human steroidogenic cytochromes P450
Valentín-Goyco, J., Liu, J., Peng, H., Oommen, J., & Auchus, R. J. (2023) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2023.106316 · Cited by 27
Shimatsu, A., Biller, B. M. K., Fleseriu, M., Pivonello, R., Lee, E. J., Leelawattana, R., Kim, J. H., Walia, R., Yu, Y., Liao, Z., et al. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej24-0153 · Cited by 25
Self-citationFleseriu, M., Pivonello, R., Newell-Price, J. D. C., Gadelha, M. R., Biller, B. M. K., Auchus, R. J., Feelders, R. A., Shimatsu, A., Witek, P., Bex, M., et al. (2025) · Pituitary · doi:10.1007/s11102-024-01471-3 · Cited by 25
Self-citationYoshida, K., Fukuoka, H., Odake, Y., Nakajima, S., Tachibana, M., Ito, J., Hosokawa, Y., Yamada, T., Miura, H., Suematsu, N., et al. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00375 · Cited by 23
Fleseriu, M., Auchus, R. J., Bancos, I., & Biller, B. M. K. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf027 · Cited by 23
Peripheral clock system circadian abnormalities in Cushing’s disease
Soares, V. R., Martins, C. S., Martínez, E. Z., de Araújo, L. D., Roa, S. L. R., Silva, L. R., Moreira, A. C., & de Castro, M. (2020) · Chronobiology International · doi:10.1080/07420528.2020.1758126 · Cited by 21
Psychological complications of Cushing's syndrome
Vives, A. S., Webb, S. M., & Resmini, E. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000633 · Cited by 21
Pivonello, R., Simeoli, C., Paola, N. D., Larocca, A., Crescenzo, E. M., & Colao, A. (2024) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2024.20.1.8 · Cited by 21
Self-citationNewell-Price, J., Fleseriu, M., Pivonello, R., Feelders, R. A., Gadelha, M. R., Lacroix, A., Witek, P., Heaney, A. P., Piacentini, A., Pedroncelli, A. M., et al. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae201 · Cited by 21
Self-citationIssa, B. G., Hanna, F., Fryer, A. A., Ensah, G., Ebere, I., Marshall, D., & Keevil, B. G. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad242 · Cited by 20
Quality of life impairment after a diagnosis of Cushing’s syndrome
Webb, S., & Valassi, E. (2022) · Pituitary · doi:10.1007/s11102-022-01245-9 · Cited by 19
Pivonello, R., Fleseriu, M., Newell-Price, J. D. C., Shimatsu, A., Feelders, R. A., Kadıoğlu, P., Tabarin, A., Brue, T. C., Geer, E. B., Piacentini, A., et al. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02359-6 · Cited by 18
Self-citationIannone, M., Dima, A. P., Sciarra, F., Botrè, F., & Isidori, A. M. (2022) · Biomedical Chromatography · doi:10.1002/bmc.5344 · Cited by 15
Self-citationTejani, S., Abramowitz, J. D., Tritos, N. A., Hamidi, O., & Mirfakhraee, S. (2024) · JCEM Case Reports · doi:10.1210/jcemcr/luae088 · Cited by 13
Fernandes, M. A., Hickle, S. D., Penna, S., Ioachimescu, A. G., & Tone, E. B. (2024) · Behavioural Neurology · doi:10.1155/2024/4393169 · Cited by 8
Karttunen, P., Tukiainen, H. O., Nykänen, S., & Saano, V. (1985) · PubMed · Cited by 6
Scheyer, N., Bertherat, J. Y., Decoudier, B., Lasolle, H., Lefèbvre, H., Drui, D., Vaillant, C., Morera, J., Castinetti, F., Cristante, J., et al. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae163.171 · Cited by 2
Cited by
Update and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome
Araujo-Castro, M., Lamas, C., Nowak, E., Newell-Price, J. D. C., Reincke, M., & Castinetti, F. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf042 · Cited by 24
Effects of metyrapone in patients with mild hypercortisolism
Musolino, A., Favero, V., Parazzoli, C., Aresta, C., Testa, S., Persani, L., Corbetta, S., Chiodini, I., & Morelli, V. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf216 · Cited by 7
Paragliola, R. M., Marchetti, M., Montagna, C., Corsello, S. M., & Peluso, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262211230 · Cited by 9
Piazzola, C., Castinetti, F., von Fabeck, K., & Simon, N. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf185 · Cited by 5
Działach, Ł., Respondek, W., Siejka, A., & Witek, P. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1629387 · Cited by 5
Metadata
- Authors
- Ferrari, D., Bonaventura, I., Simeoli, C., Tomaselli, A., Vincenzi, L., De Alcubierre, D., Sciarra, F., Rizzo, F., Cerroni, L., Di Paola, N., Minnetti, M., Sbardella, E., Venneri, M. A., Pofi, R., Pivonello, R., Gianfrilli, D., Hasenmajer, V., & Isidori, A. M.
- Affiliations
- Sapienza University of Rome (IT)
- University of Naples Federico II (IT)
- Department of Experimental Medicine, “Sapienza” University of Rome , Rome 00161 ,
- Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Diabetologia, Andrologia e Nutrizione, Università Federico II di Napoli , Naples 80131 ,
- Churchill Hospital (GB)
- Policlinico Umberto I (IT)
- Corresponding author
- Isidori, Andrea M
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2025-04-02
- Volume
- 110
- Issue
- 12
- Pages
- 3525-3537
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC12623021
- OpenAlex
- W4409093251
- Semantic Scholar
- 3e0fef2e8fad28a14b1f8da8d3696b2e32d90a75
- Cited by
- 28
- References
- 71
- Citations by year
- 2026: 15 · 2025: 13
- FWCI
- 19.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- European Union—NextGenerationEU
- Italian Ministry of University and Research (PNRR - M4C2-I1.3)
- CUP (B53C22004000006)
- Ministerial Research Project (PRIN PNRR Prot. P2022EA9RR_001)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Keywords
- Cushing's syndrome, osilodrostat, chronotherapy, once-daily dosing, diurnal cortisol rhythm, salivary cortisol, quality of life, sleep quality, deoxycorticosterone, 11-deoxycortisol, adrenal insufficiency, pituitary Cushing's disease, timing of drug administration
- MeSH terms
- Adult, Aged, Circadian Rhythm, Cushing Syndrome, Female, Humans, Hydrocortisone, Imidazoles, Male, Middle Aged, Prospective Studies, Pyridines, Quality of Life, Saliva, Sleep, Treatment Outcome, Chronotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.